Highlights and Quick Summary
- Selling, General and Administrative Expense of Revenue for the quarter ending June 30, 2022 was 37.83% (a -8.05% decrease compared to previous quarter)
- Year-over-year quarterly Selling, General and Administrative Expense of Revenue decreased by -74.8%
- Annual Selling, General and Administrative Expense of Revenue for 2021 was 184.82% (a 6.19% increase from previous year)
- Annual Selling, General and Administrative Expense of Revenue for 2021 was 174.05% (a 78.24% increase from previous year)
- Annual Selling, General and Administrative Expense of Revenue for 2020 was 97.65% (a 32.14% increase from previous year)
- Twelve month Selling, General and Administrative Expense of Revenue ending June 30, 2022 was 150.37% (a -10.89% decrease compared to previous quarter)
- Twelve month trailing Selling, General and Administrative Expense of Revenue increased by 39.89% year-over-year
Trailing Selling, General and Administrative Expense of Revenue for the last four month:
| 30 Jun '22 | 31 Mar '22 | 31 Dec '21 | 30 Sep '21 |
|---|---|---|---|
| 150.37% | 168.74% | 189.84% | 107.49% |
Visit stockrow.com/BFAGY
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical Selling, General and Administrative Expense of Revenue of Biofrontera AG Sponsored ADR
Most recent Selling, General and Administrative Expense of Revenueof BFAGY including historical data for past 10 years.Interactive Chart of Selling, General and Administrative Expense of Revenue of Biofrontera AG Sponsored ADR
Biofrontera AG Sponsored ADR Selling, General and Administrative Expense of Revenue for the past 10 Years (both Annual and Quarterly)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2022 | – | – | 37.83% | 41.14% | – |
| 2021 | 304.3% | 150.14% | 110.22% | 134.17% | 184.82% |
| 2020 | 67.35% | 141.29% | 58.42% | 168.86% | 97.65% |
| 2019 | – | 101.49% | 209.12% | 110.58% | 144.35% |
| 2018 | – | – | – | 135.27% | 145.48% |
| 2017 | – | – | 268.14% | 168.19% | 166.48% |
| 2016 | 0.0% | – | – | – | 189.51% |
Business Profile of Biofrontera AG Sponsored ADR
Sector: Healthcare
Industry: Drug Manufacturers Specialty & Generic